$131.72
2.71% yesterday
NYSE, Oct 01, 10:05 pm CET
ISIN
US66987V1098
Symbol
NVS

Novartis ADR Target price 2025 - Analyst rating & recommendation

Novartis ADR Classifications & Recommendation:

Buy
42%
Hold
48%
Sell
10%

Novartis ADR Price Target

Target Price $135.16
Price $131.72
Potential
Number of Estimates 24
24 Analysts have issued a price target Novartis ADR 2026 . The average Novartis ADR target price is $135.16. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 31 analysts: 13 Analysts recommend Novartis ADR to buy, 15 to hold and 3 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Novartis ADR stock has an average upside potential 2026 of . Most analysts recommend the Novartis ADR stock at Hold.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion $ 51.72 56.36
10.85% 8.96%
EBITDA Margin 31.96% 41.49%
14.24% 29.83%
Net Margin 23.09% 31.17%
27.46% 35.01%

22 Analysts have issued a sales forecast Novartis ADR 2025 . The average Novartis ADR sales estimate is

$56.4b
Unlock
. This is
2.76% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$60.9b 10.98%
Unlock
, the lowest is
$51.7b 5.80%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $51.7b 10.85%
2025
$56.4b 8.96%
Unlock
2026
$57.8b 2.52%
Unlock
2027
$59.6b 3.13%
Unlock
2028
$61.6b 3.32%
Unlock
2029
$63.4b 3.00%
Unlock
2030
$64.9b 2.31%
Unlock
2031
$61.3b 5.57%
Unlock
2032
$56.2b 8.20%
Unlock

18 Analysts have issued an Novartis ADR EBITDA forecast 2025. The average Novartis ADR EBITDA estimate is

$23.4b
Unlock
. This is
25.65% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$29.0b 55.86%
Unlock
, the lowest is
$17.1b 8.17%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $16.5b 26.63%
2025
$23.4b 41.45%
Unlock
2026
$23.8b 1.97%
Unlock
2027
$24.8b 4.08%
Unlock
2028
$26.1b 5.19%
Unlock
2029
$27.2b 4.12%
Unlock
2030
$29.6b 8.86%
Unlock
2031
$23.2b 21.47%
Unlock
2032
$20.4b 11.98%
Unlock

EBITDA Margin

2024 31.96% 14.24%
2025
41.49% 29.83%
Unlock
2026
41.26% 0.55%
Unlock
2027
41.65% 0.95%
Unlock
2028
42.40% 1.80%
Unlock
2029
42.86% 1.08%
Unlock
2030
45.61% 6.42%
Unlock
2031
37.93% 16.84%
Unlock
2032
36.36% 4.14%
Unlock

24 Novartis ADR Analysts have issued a net profit forecast 2025. The average Novartis ADR net profit estimate is

$17.6b
Unlock
. This is
28.65% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$18.8b 37.55%
Unlock
, the lowest is
$15.7b 15.32%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $11.9b 19.59%
2025
$17.6b 47.10%
Unlock
2026
$18.3b 4.00%
Unlock
2027
$19.8b 8.19%
Unlock
2028
$20.7b 4.98%
Unlock
2029
$21.5b 3.76%
Unlock
2030
$22.4b 4.10%
Unlock
2031
$23.3b 3.96%
Unlock
2032
$21.1b 9.36%
Unlock

Net Margin

2024 23.09% 27.46%
2025
31.17% 35.01%
Unlock
2026
31.62% 1.44%
Unlock
2027
33.17% 4.90%
Unlock
2028
33.70% 1.60%
Unlock
2029
33.95% 0.74%
Unlock
2030
34.55% 1.77%
Unlock
2031
38.04% 10.10%
Unlock
2032
37.55% 1.29%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 5.87 9.07
17.21% 54.51%
P/E 14.13
EV/Sales 4.66

24 Analysts have issued a Novartis ADR forecast for earnings per share. The average Novartis ADR EPS is

$9.07
Unlock
. This is
30.32% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$9.70 39.37%
Unlock
, the lowest is
$8.13 16.81%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $5.87 17.21%
2025
$9.07 54.51%
Unlock
2026
$9.44 4.08%
Unlock
2027
$10.21 8.16%
Unlock
2028
$10.72 5.00%
Unlock
2029
$11.12 3.73%
Unlock
2030
$11.58 4.14%
Unlock
2031
$12.04 3.97%
Unlock
2032
$10.91 9.39%
Unlock

P/E ratio

Current 18.43 25.91%
2025
14.13 23.31%
Unlock
2026
13.59 3.82%
Unlock
2027
12.56 7.58%
Unlock
2028
11.96 4.78%
Unlock
2029
11.53 3.60%
Unlock
2030
11.08 3.90%
Unlock
2031
10.65 3.88%
Unlock
2032
11.76 10.42%
Unlock

Based on analysts' sales estimates for 2025, the Novartis ADR stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.78 15.40%
2025
4.66 2.59%
Unlock
2026
4.54 2.46%
Unlock
2027
4.40 3.03%
Unlock
2028
4.26 3.21%
Unlock
2029
4.14 2.91%
Unlock
2030
4.05 2.26%
Unlock
2031
4.28 5.90%
Unlock
2032
4.67 8.94%
Unlock

P/S ratio

Current 4.32 17.25%
2025
4.20 2.69%
Unlock
2026
4.10 2.46%
Unlock
2027
3.97 3.03%
Unlock
2028
3.85 3.21%
Unlock
2029
3.73 2.91%
Unlock
2030
3.65 2.25%
Unlock
2031
3.87 5.90%
Unlock
2032
4.21 8.93%
Unlock

Current Novartis ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
BERENBERG
Locked
Locked
Locked Sep 16 2025
GUGGENHEIM SECURITIES LLC
Locked
Locked
Locked Sep 09 2025
DAY BY DAY
Locked
Locked
Locked Sep 08 2025
JEFFERIES
Locked
Locked
Locked Sep 02 2025
TD COWEN
Locked
Locked
Locked Aug 12 2025
INTESA SANPAOLO EQUITY RESEARCH
Locked
Locked
Locked Aug 08 2025
LANDESBANK BADEN-WUERTTEMBERG
Locked
Locked
Locked Jul 23 2025
Analyst Rating Date
Locked
BERENBERG:
Locked
Locked
Sep 16 2025
Locked
GUGGENHEIM SECURITIES LLC:
Locked
Locked
Sep 09 2025
Locked
DAY BY DAY:
Locked
Locked
Sep 08 2025
Locked
JEFFERIES:
Locked
Locked
Sep 02 2025
Locked
TD COWEN:
Locked
Locked
Aug 12 2025
Locked
INTESA SANPAOLO EQUITY RESEARCH:
Locked
Locked
Aug 08 2025
Locked
LANDESBANK BADEN-WUERTTEMBERG:
Locked
Locked
Jul 23 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today